Buphenini hydrochloridum - Resultados da pesquisa

mercury pharma group limited no. 1 croydon, 12-16 addiscombe road, croydon cr0 0xt, united kingdom - phenindione - tablet - phenindione 50 mg - antithrombotic agents

Malta - inglês - Medicines Authority

dindevan 10mg tablets; phenindione 10mg tablets

mercury pharma group limited no. 1 croydon, 12-16 addiscombe road, croydon cr0 0xt, united kingdom - phenindione - tablet - phenindione 10 mg - antithrombotic agents

Estados Unidos - inglês - NLM (National Library of Medicine)

probuphine- buprenorphine hydrochloride implant

titan pharmaceuticals, inc. - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz) - probuphine is indicated for the maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses of a transmucosal buprenorphine-containing product (i.e., doses of no more than 8 mg per day of subutex or suboxone sublingual tablet or generic equivalent). probuphine should be used as part of a complete treatment program to include counseling and psychosocial support. probuphine is not appropriate for new entrants to treatment and patients who have not achieved and sustained prolonged clinical stability, while being maintained on buprenorphine 8 mg per day or less of a subutex or suboxone sublingual tablet equivalent or generic equivalent. probuphine is contraindicated in patients with a history of hypersensitivity to buprenorphine or any other ingredients in probuphine (e.g., eva) [see warnings and precautions (5.11)]. risk summary the data on use of buprenorphine, the active ingredient in probuphine implant, in pregnancy, are limited;

Malásia - inglês - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

naldebain (dinalbuphine sebacate) extended release injection 75 mg/ ml.

intega sdn. bhd. - dinalbuphine sebacate -